CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM) today announced that six abstracts (including three oral presentations) will be presented at the 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting taking place November 18–21 in Seoul. At this year’s meeting, Tempus will present clinical research on rare mesenchymal tumors, highlighting how advances in molecular diagnosis and classification are unlocking new treatment options. This research leverages Tempus’ expansive, de-ident
